The stock's valuation is heavily tied to potential Supreme Court rulings and federal immunity legislation that could mitigate billions in legal liabilities, though it remains sensitive to political shifts and a 2026 EPA assessment.

Long-term bearish outlook as the administration pushes for a transition away from chemical pesticides like Glyphosate.

Faces massive and ongoing litigation risk associated with its subsidiary Monsanto's pesticide, glyphosate, with billions in damages awarded, representing a significant financial and reputational liability.

Presents a headwind for the company, as its reliance on chemical inputs like glyphosate (via its ownership of Monsanto) is contrary to the strong consumer trend towards healthy and organic food.

The historical context serves as a reminder of the long-term risks inherent in the pharmaceutical industry, where past products can lead to future reputational and financial liabilities.

Faces enormous, long-lasting legal and financial liabilities from its acquisition of Monsanto and its product Roundup, causing the stock to have suffered significantly.